The Dow Jones Industrial Average is climbing Wednesday morning with shares of UnitedHealth and Amgen seeing positive momentum for the blue-chip average. Shares of UnitedHealth and Amgen are ...

During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis [announced a failure]( ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Cantor Fitzgerald set a USD 440 target from USD 400 on October 8, 2026. Amgen stock was EUR 376.93 on October 13, 2026.

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.